A new analysis presented at CTAD 2025 by researchers at the USC Schaeffer Center offers one of the clearest pictures yet of how early intervention could transform the fight against Alzheimer’s disease. The findings show that anti-amyloid therapies, when started sooner, can meaningfully extend independence, reduce caregiver burden, and even lower the long-term costs borne by families and taxpayers.
These results reinforce a central truth: delayed diagnosis and outdated reimbursement structures are costing Americans precious years of quality life—and costing federal and state budgets billions.
Key Findings: Earlier Treatment Extends Quality of Life and Independence
Using the well-validated Future Elderly Model, the researchers simulated how patients’ lives unfold under different treatment scenarios—no treatment, treatment at “typical” diagnosis, treatment two years earlier, and treatment before symptoms appear.
Their conclusion is unambiguous:
- Treatment at typical diagnosis adds 0.56 QALYs (quality-adjusted life years) and 0.67 extra years living in the community—not in a nursing home.
- Starting treatment two years earlier increases those gains to 0.75 QALYs and 0.87 years in the community.
- Presymptomatic treatment—after a positive biomarker test but before symptoms—generates the largest improvement, adding 1.7 QALYs and 1.8 years of independent living.
For millions of families, this means more birthdays celebrated at home—and fewer months spent navigating institutional care.
The Economic Impact: Earlier Intervention Saves Money
Contrary to outdated assumptions, the study finds that earlier treatment can reduce lifetime medical costs—even though patients live longer.
Why? Because Alzheimer’s is one of the largest drivers of long-term care spending in America.
According to the analysis:
- Annual Medicaid costs could fall by up to 35% under a presymptomatic treatment strategy.
- Nursing home utilization drops significantly across all earlier-treatment scenarios.
- Treatment produces sizable medical cost offsets, particularly in late-stage care. Alzheimers_earlier_treatment_CT…
These savings directly affect taxpayers and state budgets—especially as Medicaid remains the largest payer of long-term Alzheimer’s care.
The Value to Society: Up to $307,000 Per Patient
By quantifying benefits such as:
- higher patient quality of life,
- reduced informal caregiving hours,
- caregiver well-being, and
- medical cost reductions,
the researchers estimate that presymptomatic treatment could generate up to $307,000 in lifetime value per patient. Even treatment at typical diagnosis produces over $113,000 in value.
For policymakers evaluating diagnostic access, Medicare coverage, and emerging therapies, these numbers are impossible to ignore.
What This Means for U.S. Policy
The findings validate what caregivers, clinicians, and patient advocates have been saying for years:
1. Earlier Diagnosis Must Become the Norm
Current systems delay diagnosis until symptoms are undeniable. This research shows that delay is deadly—and expensive.
2. Medicare and Medicaid Must Modernize Coverage
Restrictive coverage policies for diagnostic tools and emerging therapies risk trapping patients in the “status-quo” scenario—shorter independence, higher spending, and greater burden on families.
3. Policymakers Should Prioritize Access to Next-Generation Treatments
Emerging therapies aimed at presymptomatic patients could triple the total value delivered to patients and society.
Read the full report at USC Schaeffer by clicking here.
